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Background: Escherichia coli is believed to participate in the etiology of Crohn’s disease (CD) and possibly of
ulcerative colitis (UC), due at least in part to the observed rise in the number of these bacteria in the gut
microbiota of CD and UC patients. Nevertheless, it is not fully understood whether this quantitative variation occurs
equally throughout the mucosal and luminal spaces of the gut. To assess this question, stools and mucosa biopsies
from distinct intestinal sites were cultured aiming at determining their E. coli concentration. The cultures were
additionally screened for the presence of some virulence genes of pathogenic E. coli.
Results: Analyses of clinical materials from 14 controls (38 biopsies and 14 stools samples), 11 CD (25 biopsies and
11 stools samples) and 7 UC patients (18 biopsies and 7 stools samples) indicated no significant variation in the
number of E. coli present in stools, but a rise of at least one log10 CFU/mg in biopsies from the ileum of CD
patients and the sigmoid and rectum of CD and UC patients. The cultures were screened for the presence of E. coli
attaching and effacing (eae), invasion plasmid antigen H (ipaH), aggregative adherence transcriptional activator
(aggR), Shiga cytotoxins (stx), and heat labile enterotoxin (elt) and the following serine proteases autotransporters of
Enterobacteriaceae (SPATE) genes: plasmid encoded toxin (pet), secreted autotransporter toxin (sat), Shigella
extracellular protein (sepA), protein involved in intestinal colonization (pic) and Shigella IgA-like protease homolog
(sigA). Six of the 10 genes screened were detected in the total of samples investigated: aggR, eae, pet, sat, sepA and
sigA. No difference in the prevalence of any of these markers was observed in cultures from different clinical
materials or groups of patients.
Methods: Bacterial quantitation was carried out following cultures of diluted samples suspensions in MacConkey
agar, Wilkins Chalgren agar for anaerobes, E. coli/coliform chromocult agar, and blood agar. Screening for E. coli
virulence genes was performed by multiplex PCR of DNA purified from total MacConkey undiluted broth cultures.
Conclusion: In CD and UC patients only the mucosa associated population of E. coli is augmented and the
proliferation is prominent in the ileum of CD and rectum and sigmoid of both UC and CD patients which are sites
where the lesions usually are observed. The augmented E. coli population in these sites presented a low number of
the virulence markers, possibly meaning that they are not relevant for the disease process.
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Intestinal microbiota is one of the many factors asso-
ciated with the cause or complications of the symptoms
of inflammatory bowel diseases (IBD). Microbial partici-
pation might result from dysbiosis, the action of a par-
ticular pathogen, or both. As a dominant facultative
aerobe of the colon, Escherichia coli has long been con-
sidered among the candidate IBD pathogens. Results
reported thus far [1-3] indicate that IBD patients experi-
ence a rise in the population of these bacteria. Yet, due
to methodological variations regarding the source of the
samples (stools vs. mucosa), quantitation method (cul-
ture dependent vs. independent), and histopathological
activity of the sampled tissue (inflamed vs. no inflamed),
the conclusions of different works are not always coinci-
dent. Some reports indicate an increase in mucosa-
associated E. coli population only in Crohn’s disease
(CD) [1]; others sustain that this elevation is also
observed in ulcerative colitis (UC) [3]. The contribution
of mucosa-associated bacteria is more relevant than the
lumen residing bacteria to the formation of mucosal
lesions [4]. While cultures of mucus depleted colonic bi-
opsies from controls are sterile, cultures under the same
treatment of corresponding biopsies taken from CD
patients show a high number of E. coli [1]. Rise in
mucosa-associated E. coli from CD patients has also
been demonstrated in an immunohistological study
using polyclonal antibodies directed to E. coli antigens
[5]. Analyses by temperature gradient gel electrophoresis
of 16SrDNA/RNA amplicons from fecal bacteria of UC
patients demonstrated a lower bacterial diversity asso-
ciated with not only the dominance but with the activity
of E. coli [2]. The proliferation of E. coli in a given gut
mucosal site seems not to correlate with the occurrence
of inflammation and the exceeding E. coli carries few or
no traditional virulence markers [3]. Differences seem to
exist regarding the ability of E. coli isolates from CD and
UC cases in triggering the processes responsible for the
characteristic lesions of each of these IBD. According to
Rhodes [4] in CD, the bacteria enter the lymphoid tissue,
via M cells, persist within regional macrophages leading
to granulomatous inflammation, which underlies clinical
manifestations, such as ulcerations, obstructions and fis-
tulas. Around 36-40% of E. coli isolates from CD
patients show the ability to invade epithelial cells [6,7]
and the virulence potential of the adherent and invasive
E. coli (AIEC) is well recognized [8]. In UC, flagellin
mediated bacteria interaction with TLR-5 on mucosa cell
surface prompts IL-8 release and ensuing neutrophil re-
cruitment and activation [4]. The flagellin access to cell
basolateral exposed TLR-5 is thought to be facilitated by
the abnormally permeable mucosa seen in UC. Recent
work reported a high prevalence, in rectal biopsies of UC
patients, of enteroaggregative adherent E. coli (EAEC) [9],a typically non-invasive pathovar, whose virulence attri-
butes include the induction of mucus secretion by goblet
cells, of IL-8 release by mucosal cells, and biofilm forma-
tion [10] – features that could indicate an eventual role
for these bacteria in the pathogenesis of UC. Most of stud-
ies aiming at determining variation in the concentration
of E. coli in IBD analyses luminal or mucosa associated
bacteria. In the present work, by investigating stools and
mucosa biopsies samples from distinct gut sites, we show
that while no quantitative case–control variation is
observed in E. coli population from stools, the number of
these bacteria residing in particular gut mucosal sites of




Bacterial quantitation was performed by counting of col-
onies grown in cultures seeded with samples suspen-
sions, and expressed as log10 of the number of colonies
forming units per milligram (CFU/mg). The suspensions
were cultured in aerobic conditions in MacConkey agar,
chromocult for coliforms agar and blood agar, and an-
aerobically in Wilkins-Chalgren agar. When compared
with controls, although most samples from both CD and
UC showed higher bacteria numbers in the four culture
media employed, statistically significant differences were
observed only for biopsies samples, but not for stools
cultured in any of media, for either of the IBD patients
groups. By comparison of cultures from sigmoid and
rectum (S/R) biopsies of CD patients with controls in all
media tested, the number of CFU for biopsies of the CD
patients was at least of one log10 unit higher. Superior
bacterial concentration of this same magnitude was also
seen for S/R biopsies from UC patients in MacConkey,
chromocult and Wilkins-Chalgren agar cultures. The
same was observed for ileum biopsies from both UC and
CD patients and for right colon biopsies from UC
patients in MacConkey agar cultures (Figure 1A). Count-
ing results in chromocult agar revealed no significant
differences in the number of non-E. coli coliforms (green
and red colonies) for biopsies of any gut site from both
UC and CD. However, positive variation in the number
of E. coli (purple colonies) was ca. 1.5 and 2.0 log10
units, respectively for ileum and S/R biopsies from CD
patients and ca. 1.5 log10 units for S/R biopsies of UC
patients (Figure 1B). The E. coli identity of purple col-
onies from chromocult cultures of every clinical sample
was checked by biochemical tests. Fewer than 2% of
these colonies had not their E. coli identity confirmed.
Virulence genes
MacConkey broth cultures from 67 distinct clinical sam-








































Figure 1 Average bacterial concentration (CFU/mg) in distinct clinical samples from Controls (white bars), Crohn’s Disease (grey bars)
and ulcerative colitis (dark bars) patients. A, Total counting in MacConkey agar cultures; B, Purple colonies counting in brilliance E. coli/
coliform agar cultures. IL, RC, LC, S/R, ST, respectively, biopsies from ileum, right colon, left colon, sigmoid and rectum and stools. Asterisks
indicate values with significant differences (P<0.05, Paired t-test) in comparisons with controls. See Table 2 for numbers of samples analysed per
clinical material.
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PCRs – one for presence of Diarrheagenic E. coli (DEC)
typical virulence genes [E. coli attaching and effacing
(eae), invasion plasmid antigen H (ipaH), aggregative ad-
herence transcriptional activator (aggR), Shiga cytotoxins
(stx), and heat labile enterotoxin (elt)] and other for the
following serine proteases autotransporters of Enterobac-
teriaceae (SPATE) genes: plasmid encoded toxin (pet),
secreted autotransporter toxin (sat), Shigella extracellular
protein (sepA), protein involved in intestinal colonization(pic) and Shigella IgA-like protease homolog (sigA). Six of
the 10 genes screened were detected in the total of sam-
ples investigated (Figure 2 and Table 1): aggR, eae, pet, sat,
sepA and sigA. With the exception of pet, which was
detected only in controls, all of the remaining genes were
found in samples from both IBD and control patients. The
most common genetic markers detected were the SPATEs
sat and sigA genes. There was no statistically significant
difference in the prevalence of any of the genes searched
for in comparisons between cases and controls for a given
Figure 2 DNA amplified by multiplex PCR, with primers for
Diarrheagenic E.coli typical virulence genes (MDEC), and serine
protease autotransporters of Enterobacteriaceae (SPATE) genes
(MSPATE). Lanes 1–4, Reference strains; lanes 5–10, Pools of Gram
negative bacteria (growth in MacConkey broth) from some clinical
samples (see Table 1). Lane 11, 1kb DNA ladder..
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given subject.
Discussion
As an indigenous organism of the gut, E. coli was for
long considered unsuspected of causing intestinal dis-
eases [11] but over last decades, following the descrip-
tion of multiple enteric E. coli pathovars and their
epidemiological association with enteritis, it became one
of the most relevant human and animal bacterial entero-
pathogens, associated with several gastrointestinal dis-
eases ranging from food poisoning to different clinical
manifestations of diarrhea [12]. Accumulated evidences
lend support to its involvement with the etiology of IBD
as well, in particular with CD, wherein AIEC is thought




CO (4) CD (6) UC (3) CO (6) CD (5) UC (4) CO (
aggR 1 1 1 1
eae 1 1 1
pet 1
sat 1 1 1 3 2 3 1
sepA 1 1 1
sigA 1 2 1 2 2 3 1
a CO, Controls; CD, Crohn’s Disease; UC, Ulcerative Colitis.
b ( ), Number of samples tested.formation of the epithelioid granulomas [8] typically
found in histological preparations of gut biopsies
from CD patients. Elevation in the number of E. coli
in the gut of IBD patients [13] and in serum anti-
bodies titers against some of its antigens [14,15] are
among the first clues of its role in this disease. Rise in
E. coli number was demonstrated in stools [2] and
mucosa of distinct gut sites [1,3,16]. The increase in
E. coli number in IBD patients has also been corre-
lated with disease activity [13].
To get a broad picture of the quantitative variation in
E. coli population from IBD patients, we have analysed
cultures on E. coli/coliform agar of samples from at least
two distinct clinical materials per patient, consisting of
stools and/or biopsies of different gut sites of controls
and individuals diagnosed with CD and UC. Statistically
significant case-controls differences in the number of
bacteria were observed only in E. coli counting for cul-
tures derived from particular mucosal sites, namely
ileum of CD and sigmoid and rectum of both CD and
UC patients, which showed a higher bacterial concentra-
tion, in comparisons with corresponding sites of con-
trols. In contrast to previous observations [3], the
increase in E. coli number reported here was not accom-
panied by a rise in the number of non-E. coli coliforms.
MacConkey broth cultures from sample suspensions
of each clinical material were PCR screened for ten viru-
lence genes, five of which recognized as markers for
Diarrheagenic E. coli (DEC) detection [12,17], and five of
them corresponding to the SPATE genes pet, sat, sigA,
pic and sepA. Of the five DEC genes screened, only eae
and aggR were detected, in 5 of the 67 samples tested
(Table 1). The low prevalence of DEC genes in cultures
of these IBD clinical samples are not too different from
the results of other investigators, who screening bacterial
isolates, found no E. coli positive for any of these mar-
kers [3,16]. Also, the low prevalence of these classical
DEC virulence genes in IBD clinical samples is in agree-
ment with previous observations arguing that IBD E. coliroth cultures of distinct clinical samples from each groups
inical sample a,b
Left colon Rectum/sigmoid Stools




1 1 1 1 3 1
1 3 1 2 3 1
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coli (ExPEC) [3,4].
The reasoning for the search of SPATE genes among
IBD clinical samples took in account not only the wide
distribution of SPATE among DEC and ExPEC isolates
[18] but also the variety of biological activities of these
proteases [19], which could eventually play some role in
the pathogenesis of IBD. Furthermore, EAEC, a pathovar
showing high prevalence of SPATE genes [20] were re-
cently found to be dominant among IBD E. coli isolates
[9]. With the exception of pic, all the remaining of the
five SPATE genes searched for were found among the
samples screened, with sat and sigA identified in nearly
all of them. Nevertheless, no statistically significant dif-
ferences could be observed in the prevalence of any of
the SPATE genes identified (pet, sat, sepA and sigA)
among the different clinical samples or groups of
patients investigated. In the work by Kotlowski et al. [3],
where a PCR screening for 8 SPATE genes was carried
out, a higher prevalence of SPATE positive E. coli were
found among isolates from IBD patients as compared to
controls. Since in their analyses they used pure E. coli
cultures instead of total Gram negative cultures from
the samples, the nature of the PCR target as well as the
number of genes searched for might explain the
observed divergence in relation to our results.
The proliferation of E. coli raises the question whether
the exceeding bacteria plays an active or secondary role
in IBD etiopathogenesis. The prevalence of haemolytic
and necrotoxic E. coli strains has been shown to be
higher in patients in relapsing UC, but follow-up ana-
lyses demonstrated that these bacteria tended to follow
rather than precede the onset of relapse attack [13]. On
the other hand, AIEC has being detected in proportion
as high in early as in chronic ileal lesions of CD patients
[6]. It is believed that in CD, the bacterial adhesion is
favoured by abnormal receptors exposition in cell sur-
face of genetically susceptible hosts [8]. Soluble plant
fibers, to which a therapeutic potential in treatment of
CD has been attributed, are able to inhibit this bacterial
adhesion [1].
Although previous report suggests an active rather
than secondary role for E. coli in IBD, on the basis of a
high prevalence of strains possessing virulence markers
in IBD patients [3], this indication is not supported by
the data of the present work. By using as PCR target
gross (total) Gram negative bacteria cultures which are
more representative than a few colonies of the bacterial
population in the samples, we were unable to detect dif-
ference in the prevalence of the E. coli virulence genes
searched for among distinct groups of patients or clinical
material investigated here. The genes consisted of five
markers traditionally used for identification of DEC and
five SPATEs genes, categories of proteases which up todate were not found in non-pathogenic organisms [18].
Moreover, the bacteria proliferation in IBD patients was
noticed in sites where the lesions are prominent and
usual, namely the ileum, sigmoid and rectum in CD and
the sigmoid and rectum in UC. The apparently non-
random E. coli abundance in these sites and its unaltered
number in stools do not preclude the possibility that
they represent secondary local colonizers. Also, in view
of their localization, luminal bacteria could be a more
direct target for drugs interfering with bacterial species
composition of the gut, and thus the history of drugs in-
take could explain why the increment in the number of
mucosa colonizing E. coli was not also observed for lu-
minal population of these bacteria, among IBD patients.
Despite of the low number of genes searched for and the
restricted quantity of some samples, such as left side
colon, the uniform distribution of virulence genes
among the various clinical materials in controls and IBD
patients might indicate an irrelevance of these factors
and/or the E. coli pathovars marked by them for the
pathogenesis of IBD.
There are numerous evidences to support the involve-
ment of E. coli with CD and hence AIEC is recognized
as new pathovar within the species [21], but the link of
E. coli with UC is not as clear. We speculate that in UC,
and eventually in CD, aggregative adherent E. coli might
play some role, at least in aggravating already established
inflammatory processes. This group of bacteria, which is
extremely heterogeneous in regard to expression of viru-
lence factors and pathogenic potential, is classified in
typical and atypical EAEC, based upon the presence of
the aggR transcriptional activator of virulence genes in
the first and absence in the last [21]. Atypical EAEC
includes commensal, intestinal and extra-intestinal
pathogenic E. coli. Testing some E. coli isolates derived
from the Gram negative cultures studied here for the
ability to adhere to Hep-2 indicated the presence of
atypical EAEC in samples from IBD cases (data not
shown). With the characterization of these bacteria pres-
ently under way in our laboratory we hope to get rele-
vant information which will be of help in understanding
their proliferation in the gut mucosa of IBD patients.
Conclusion
Analyses of samples from stools and biopsies of different
intestinal mucosa sites from controls and patients diag-
nosed with CD and UC indicate that while the number
of E. coli is unaltered in the stools, the amount of these
bacteria is higher in ileal biopsies from CD and in the
sigmoid and rectum of both CD and UC patients. Tests
for DEC virulence markers and some SPATE genes did
not show any difference in the prevalence of these genes
in the augmented E. coli population. The elevation of
these bacteria in sites where the lesions usually appear
Table 2 Number of mucosal biopsies and stools analysed
per group of patients
Clinical sample Groupsa,b
CO (14) CD (11) UC (7)
Ileum 7 6 5
Right colon 10 7 6
Left Colon 11 3 3
Rectum/sigmoid 10 9 4
Stools 14 11 7
a CO, Controls; CD, Crohn’s Disease; UC, Ulcerative Colitis.
b ( ), Numbers of patients.
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ondary to the initiation of the inflammatory processes.
Methods
Patients and clinical samples
The study groups comprised of subjects attending the
UNESP University Hospital, Botucatu SP Brazil, for rou-
tine colonoscopy who fulfilled the following inclusion
criteria: patients not under antibiotic therapy and not
having history of infectious intestinal diseases for at least
2 months before the examination and who agreed, by
signing a Consent Form, with the destination of part of
their clinical materials for research purposes. All the
procedures regarding the approaching of the patientsTable 3 Virulence genes, primers and DNA target sequence si




















R-CCATTATCACCAGTAAAACGCACCwere approved by the local Committee on Ethics in Re-
search. A number of 11 subjects diagnosed with CD, 7
with ulcerative colitis (UC), and 14 Controls were inves-
tigated. The IBD diagnosis was based on clinical, colono-
scopic and histopathological criteria [22,23]. The controls
group comprised of individuals who not fulfilled the diag-
nosis criteria for IBD, showing no detectable intestinal
pathology or intestinal bleeding of non IBD or non-
infectious origin. Clinical materials included stools and
mucosal biopsies from the ileum and different parts of the
large intestine (Table 2). Most of biopsies were sampled
from sites showing no detectable or mild endoscopic
activity. A number of at least two distinct clinical sam-
ples, including stools and biopsies, from each patient
were taken (Table 2). After collection, the stools were
maintained in refrigerator for ca. 72 h before prepar-
ation for bacterial cultures.
Bacterial cultures
Unless otherwise indicated, all the culture media and
reagents for bacterial cultures were manufactured by
Oxoid (Basingstoke, Hampshire, England). Incubation
temperature for all cultures below was 37°C. Samples
weighting ca. 5–15 mg of freshly (within 3 h after colon-
oscopy) collected biopsies or refrigerated stools were
vortexed in 100 μl of 0.9% sterile saline dispensed in 2
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tubes. Half of sample suspension was transferred to
MacConkey Broth and the remaining volume was sub-
jected to serial (decimal) dilutions for bacterial quantita-
tion in each of the following agar media: MacConkey,
brilliance E. coli/coliform, Wilkins-Chalgren anaerobe
and nutrient agar supplied with 5% defibrinated sheep
blood. Wilkins Chalgren anaerobe cultures were grown
for 48 h within anaerogen O2-depleted sealed jar. Cul-
tures in the other media were grown for 18–24 h under
atmospheric oxygen tension. The total of bacterial col-
onies in each agar plate was counted and the number of
UFC/mg of sample calculated according to the suspen-
sion dilution. Aliquots of 50 μl of MacConkey broth cul-
tures were transferred to brain hearth infusion broth,
incubated overnight, and the resulting growth was frozen
with 15% glycerol at −80°C. These Gram negative bacteria
(GNB) pools were used for E. coli recovery and DNA puri-
fication for PCR. The presence or absence of E. coli in
each sample was confirmed by biochemical identification
of purple colonies grown overnight in Brilliance E. coli/
coliform agar streaked with GNB pools. A number of
5–15 colonies from these cultures were individually
inoculated in MacConkey, semi-solid MILi, modified
Rugai [24] and Simmons citrate agars (BBL, Cockeysville,
USA) wherein the following reactions could be detected:
urease, indole, and H2S production, lactose and glucose
fermentation, gas from glucose fermentation, utilisation of
sodium citrate as single carbon source, bacterial move-
ment, lysine decarboxylation and L-tryptophan deamin-
ation. Those colonies showing positive results for indole
and glucose fermentation and negative results for H2S,
L-tryptophan deamination and urease production were
considered as E. coli.
Virulence genes detection
Genomic DNA was purified from overnight cultures
grown in Luria Broth inoculated with 20 μl of stocked
GNB pools utilising the QIAmp mini kit (Qiagen, Hilden
Germany). Each bacterial pool DNA was PCR screened
with primers specific for genes typically found in Diar-
rheagenic E. coli (DEC) (eae, stx, elt, aggR, and ipaH)
and serine proteases autotransporters of Enterobacteria-
ceae (SPATE) encoding genes (Table 3). For SPATE
genes detection, the samples were first screened by a
monoplex PCR using generic primers targeting genes of
common sequences [3]. SPATE+ samples were then
tested by multiplex PCR using primers specific for each
of the following individual SPATE genes: pet, sat, sepA,
pic and sigA, (see reference [20] and Table 3). Screening
for DEC genes was performed by multiplex PCR accord-
ing to Toma et al. [17], and for individual SPATEs
according to Boisen et al. [20]. Positive controls used in
all PCR were the following E. coli reference strains:EDL933, for eae and stx; 40T, for elt, O42, for aggR and
pet and EIX, for ipaH. Shigella flexneri 2a strain 2457T
was used as positive controls for sat, sepA, pic and sigA.
Negative control for the PCRs was E. coli K12 HB101.
Strain EDL933 was gently provided by Dr. I. C. A.
Scaletsky from UNIFESP Medical College, SP Brazil,
and S. flexneri 2a 2457T by Dr J. B. Kaper from Center for
Vaccine Development, University of Maryland, USA. PCR
master mix components were used as commercial kits, to
which the template DNA and primers were added, follow-
ing manufacturer instructions. Qiagen multiplex kit
(Qiagen, Valencia, USA) and NEB Taq 5X master mix
(NEB, Hitchin, UK) were used in multiplex and monoplex
PCR, respectively and the oligonucleotides were synthe-
sized by Eurofins (Eurofins MWG Operon, Huntsville,
USA). The PCRs were run in a MasterCycler ProS Ther-
mocycler (Eppendorf, Hamburg, Germany).
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